羟考酮缓释片联合唑来膦酸治疗骨转移癌痛的效果观察

Effect of hydroxycodone sustained-release tablet combined with zoledronic acid in the treatment of bone metastasis cancer pain

目的:回顾性分析羟考酮缓释片联合唑来膦酸在恶性肿瘤骨转移癌痛治疗中的临床效果和不良反应。方法:选择64例恶性肿瘤伴骨转移癌痛的病人,其中采用羟考酮缓释片联合唑来膦酸治疗的病人归为观察组,单独使用羟考酮缓释片治疗的病人归为对照组。回顾性分析病人羟考酮缓释片的用量、不良反应以及病人的疼痛评分及生活质量。结果:2组在首次滴定后羟考酮缓释片用量、生活质量、疼痛数字评分(NRS)差异无统计学意义(P>0.05)。治疗2周后,2组之间羟考酮缓释片用量、治疗4周后2组之间生活质量差异均有统计学意义(P<0.05),而疼痛NRS评分无统计学意义(P>0.05)。不良反应主要是便秘、恶心、呕吐、嗜睡、尿潴留、谵妄、认知障碍等,2组差异有统计学意义(P<0.05)。结论:联合唑来膦酸治疗骨转移癌痛可以减少羟考酮缓释片的用量,提高生活质量,降低不良反应发生率。

Objective:To analyze the clinical effects and adverse reactions of oxycodone sustained-release tablet combined with zoledronic acid in the treatment of malignant tumor bone metastasis pain. Methods:Sixty-four patients with malignant tumor complicated with bone metastasis pain were selected. The patients treated with oxycodone sustained-release tablet combined with zoledronic acid and oxycodone sustained-release tablet were divided into the observation group and control group,respectively. The dosage of oxycodone sustained-release tablet,adverse reaction,pain score and quality of life in two groups were retrospectively analyzed. Results:There was no statistical significance in the dosage of oxycodone sustained-release tablet,quality of life and NRS score between two groups after the first titration(P >0. 05). The differences of the dose of oxycodone sustained-release tablet after two weeks of treatment,and quality of life after four weeks of treatment between two groups were statistically significant(P < 0. 05),and the difference of the NRS score between two groups was not statistically significant(P > 0. 05). The differences of the adverse reactions,which included constipation, nausea,vomiting,lethargy,urinary retention,paralysis and cognitive impairment,were statistically significant between two groups(P < 0. 05). Conclusions:Zoledronic acid in treating bone metastasis cancer pain can reduce the dosage of oxycodone sustained-release tablet,improve the quality of life,and reduce the incidence rate of adverse reactions.